The global monoclonal antibodies market was valued at USD 256.60 billion in 2024 and is forecasted to expand at a CAGR of 11.2 %, demonstrating that national strength in biologics R&D, regulatory policy, and infrastructure will define leadership. This country-level analysis spotlights how powerhouse markets—such as the U.S., China, Germany—and innovation hubs shape global mAb...